Generic Glatiramer Acetate (Copaxone)
Multiple Sclerosis
Key Facts
About Natco Pharma
Natco Pharma's mission is to deliver affordable, high-quality medicines for complex and life-threatening conditions, primarily through the development and manufacture of generic drugs and active pharmaceutical ingredients (APIs). The company has achieved notable success, particularly with its pioneering launch of a generic version of the hepatitis C drug sofosbuvir in India, which dramatically reduced treatment costs and expanded access. Its strategy centers on vertical integration, targeting therapeutic areas with high unmet need and significant cost burdens, and leveraging its expertise in reverse engineering and complex formulation to secure first-to-file and first-to-market opportunities globally.
View full company profileTherapeutic Areas
Other Multiple Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| SPU-16 | Silo Pharma | Preclinical |
| Electroceutical® Therapy | Endonovo Therapeutics | Research |
| BTK allosteric inhibitor | Acellera | Pre-clinical |
| CLS12311 | Cellerys | Phase 2 |
| Interferon-beta variants | Heligenics | Pre-clinical |
| G-NK cells | Indapta Therapeutics | Phase 1 |
| MS Biomarker Research | Rune Labs | Research |
| AVT001 | Avotres | Phase 2b |
| Evobrutinib | Merck KGaA | Phase 3 |
| Undisclosed MS Program | Astoria Biologica | Pre-clinical |
| PV-3212 | Provid Pharma | Pre-clinical |
| REBIF (interferon beta-1a) | EMD Serono | Approved |